IMC breaks down and analyzes key developments in the life sciences sector for our members, policy influencers, and Canadians.
Here, you’ll find IMC’s latest press releases, reports, policy papers, infographics, and other resources on the issues shaping our industry.
The private drug insurance market in Canada saw a 7.3% total cost growth in 2023-2024, primarily driven by increased utilization which accounted for 60% of total cost growth. The number of claimants rose by 3.5%, with claimants making
0.9% more claims.
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (736 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
Use this tool to search for brand name drugs to view their current negotiation status.
Learn more about the negotiation process from the pCPA.
One of Innovative Medicines Canada’s guiding principles is to offer solutions to challenges in the Canadian health system. Access to new medicines is one such challenge.
Use this beginner’s guide to understand the basics of how our industry works.
Everything you need to make an informed decision about our industry.
Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Stay informed with timely, relevant content on key issues shaping our industry.
